- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06637150
Dalpicilib-Enhanced vs. Standard Endocrine Therapy in ER+ HER2- Early Breast Cancer
A Phase III Randomized Controlled Trial Comparing Dalpicilib-Enhanced Adjuvant Endocrine Therapy With Standard Adjuvant Endocrine Therapy in ER+ HER2- Lymph Node-Negative Early Breast Cancer With Risk Factors
This study aims to conduct a randomized controlled clinical trial to compare the efficacy and safety of dalpicilib combined with endocrine therapy versus standard endocrine therapy in ER-positive, HER2-negative, lymph node-negative patients with risk factors, in order to further optimize the regimen for adjuvant endocrine therapy in breast cancer.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Zhimin Shao
- Número de teléfono: 86-021-64175590
- Correo electrónico: zhimingshao@fudan.edu.cn
Ubicaciones de estudio
-
-
-
Shanghai, Porcelana
- Reclutamiento
- breast cancer institute of Fudan University Cancer Hospital, shanghai, shanghai
-
Contacto:
- Zhimin Shao, MD
- Número de teléfono: 86-021-641755901105
- Correo electrónico: zhimingshao@fudan.edu.cn
-
Investigador principal:
- Zhimin Shao, MD
-
Sub-Investigador:
- Keda Yu, MD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Women aged 18-70 years
- ECOG score of 0-1
- Histologically confirmed unilateral invasive cancer (regardless of pathology type)
- No macroscopic or microscopic tumor residue after surgical resection
- Early-stage breast cancer, pathologically confirmed as ER-positive and HER2-negative (ER-positive defined as immunohistochemical detection of ER >10% of tumor cells positive; HER2 0-1+ or HER2 2+ but FISH negative, with no amplification, defined as HER2-negative)
- Postoperative pathological staging of pT1c or above, N0M0, and meeting one of the following criteria: (1) G3; (2) G2 and meeting one of the following: i. Ki-67 ≥20%; ii. 21-gene recurrence score ≥26 or high genomic risk profile; iii. Age ≤40 years and vascular invasion positive
- No prior neoadjuvant treatment
- Time from surgery or completion of chemotherapy or radiotherapy (whichever occurs later) to randomization does not exceed 8 weeks
- Good postoperative recovery, at least 1 week after surgery
- Normal function of major organs, meeting the following criteria: (1) Hematological criteria: HB ≥90 g/L (no blood transfusion in the last 14 days); ANC ≥1.5 × 10^9 /L; PLT ≥100 × 10^9 /L; (2) Biochemical criteria: TBIL ≤1.5 × ULN (upper limit of normal); ALT and AST ≤3 × ULN; serum Cr ≤1.5 × ULN
- Women of childbearing age must use contraception during treatment
- Subjects voluntarily join this study, sign informed consent, demonstrate good compliance, and cooperate with follow-up
Exclusion Criteria:
- Bilateral breast cancer or ductal/lobular carcinoma in situ (DCIS/LCIS)
- Received treatment for advanced disease
- Metastasis at any site
- Any tumor > T4a (with skin involvement, fixation, inflammatory breast cancer)
- Clinically or radiologically suspected malignancy in the contralateral breast not confirmed and requiring biopsy
- Received neoadjuvant therapy, including chemotherapy, radiotherapy, and endocrine therapy
- History of malignant tumors within the past 5 years (excluding basal cell carcinoma of the skin and cervical carcinoma in situ), including contralateral breast cancer
- Patient has been enrolled in other clinical trials
- Patient has severe systemic diseases and/or uncontrolled infections that prevent participation in the study
- Severe cardiovascular or cerebrovascular diseases within 6 months prior to randomization (e.g., unstable angina, chronic heart failure, uncontrolled hypertension >150/90 mmHg, myocardial infarction, or stroke)
- Known allergy to relevant medications
- Women of childbearing age who refuse contraception during treatment and for 8 weeks after treatment completion
- Pregnant or breastfeeding women
- Positive pregnancy test before drug administration after joining the trial
- Individuals with mental illness or cognitive impairment who cannot understand the trial protocol and its side effects, unable to comply with the protocol and follow-up (systematic assessment required prior to enrollment)
- Individuals without personal freedom and independent civil capacity
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: standard endocrine therapy
standard endocrine therapy |
standard endocrine therapy |
|
Experimental: standard endocrine therapy plus dalpicilib
standard endocrine therapy plus dalpicilib |
standard endocrine therapy Dalpicilib 100 mg once daily from day 1 to day 21, every 4 weeks, for a total of 3 years, in combination with endocrine therapy for 5 years. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Invasive Disease Free Survival
Periodo de tiempo: From enrollment to 3 years post-treatment
|
Invasive Disease Free Survival |
From enrollment to 3 years post-treatment
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Supervivencia libre de enfermedades de 3 años
Periodo de tiempo: Desde la inscripción hasta los 3 años post-tratamiento
|
Desde la inscripción hasta los 3 años post-tratamiento
|
|
|
Overall Survival
Periodo de tiempo: From enrollment to 3 years post-treatment
|
Overall Survival |
From enrollment to 3 years post-treatment
|
|
safety
Periodo de tiempo: From enrollment to 3 years post-treatment
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 |
From enrollment to 3 years post-treatment
|
|
Patient reported outcomes
Periodo de tiempo: From enrollment to 3 years post-treatment
|
Patient-Reported Outcomes (PROs) Assessed by the EORTC QLQ-C30 Questionnaire. Provide a brief description of what aspects of the patient's health or experience the tool will measure (e.g., quality of life, symptom burden, treatment side effects). |
From enrollment to 3 years post-treatment
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- SCHBCC-N081
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .